BCL3 and hepatocellular carcinoma: The clinical utility of BCL-3 as a marker of prognosis is highlighted by a growing number of clinical studies: increased protein and mRNA expression has been associated with adverse clinicopathological characteristics in hepatocellular carcinoma patients (43).